CompletedPhase 4

Ketoconazole Foam 2% for the Treatment of Versicolor

United States11 participantsStarted 2008-11

Plain-language summary

Ten adult patients age 19 and older with a clinical diagnosis of tinea versicolor, as well as a positive Potassium Hydroxide (KOH) using calcofluor. Ketoconazole 2% foam will be used to determine its effectiveness, safety and satisfaction when used to treat tinea versicolor.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Male or female patients, aged 19 years and over.
✓. Clinical presentation of tinea versicolor.
✓. Positive KOH using calcofluor.
✓. The ability to provide informed consent (including photography release)

Exclusion criteria

✕. Use of topical antifungal to the affected area in the past 30 days
✕. Use of topical steroid to the affected area in the past 14 days
✕. If female, positive urine pregnancy test at screening (female patients of childbearing potential must be practicing a reliable method of birth control, not be planning a pregnancy, not be breast-feeding during the study)
✕. Patients with a dermatologic condition in the region of the treatment site that in the investigator's opinion may interfere with the study results
✕. Current diagnosis of immunocompromising conditions
✕. Any medical or psychiatric condition that may interfere with treatment or compliance

What they're measuring

The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor

Timeframe: 4 weeks

Trial details

NCT IDNCT00830388

SponsorBoni Elewski, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-08

Results submitted2012-05-01

View on ClinicalTrials.gov More Tinea Versicolor trials